TrialCancer2020
A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
Richard D Kim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
this paperpooled ittrialcites it
TrialCancer2020
Richard D Kim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.